Search | Clinical Trials Finder

Conditions: Urea Cycle Disorder
Interventions: Acetohydroxamic Acid Oral Tablet, No treatment; Drug · Other
Lead sponsor: Nicholas Ah Mew; Other
Eligibility: 18 Years to 60 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: maltodextrin, super starch; Dietary Supplement
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Preterm Infant
Interventions: Early/Slow, Early/Fast, Late/Slow, Late/Fast; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 32 Weeks
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fatty Liver
Interventions: possible liver biopsy and serum collection; Procedure
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Basal Insulin Titration Application; Device
Lead sponsor: Amalgam Rx, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Healthy Volunteers
Interventions: Mobocertinib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Performance vs. Effort Rewards
Interventions: Performance Rewards, Effort Rewards; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 9 Years to 13 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Davis, California

Conditions: Pharmacology
Interventions: Abiraterone: Treatment A, Abiraterone: Treatment B, Abiraterone: Treatment C, Abiraterone: Treatment D; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 25 Years to 35 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Cypress, California

Conditions: Formulation Bridging, Food Effect
Interventions: PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Type 2 Diabetes Mellitus
Interventions: Alogliptin, Metformin, Glipizide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 94
States / cities: Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more

Conditions: Healthy
Interventions: Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hip Fractures, Tibial Fractures, Ankle Fractures, Humeral Fracture, Proximal, Distal Radius Fracture
Interventions: All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.; Other
Lead sponsor: AO Innovation Translation Center; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more

Conditions: Metabolic Syndrome, Pre-diabetes
Interventions: Time-restricted eating (TRE) + Standard of Care, Standard of Care; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy
Interventions: PF-06821497 Treatment A, PF-06821497 Treatment B, PF-06821497 Treatment C, PF-06821497 Treatment D, PF-06821497 Treatment E, PF-06821497 Treatment F; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neoplasms
Interventions: GSK3326595, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • New York, New York + 3 more

Conditions: Aging
Interventions: Experimental: Locomotor Learning; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Volunteers
Interventions: AZD9291; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Mass Balance Recovery
Interventions: [14C]-D-0502; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metabolic Syndrome, Postmenopausal Symptoms
Interventions: Time-Restricted Feeding (TRF); Behavioral
Lead sponsor: Julie Pendergast; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Opioid Dependence
Interventions: Suboxone Sublingual Film, Zubsolv sublingual tablets; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects
Interventions: Vorasidenib 40 mg Oral Tablet, Ciprofloxacin 500 mg Oral Tablet, Vorasidenib 10 mg Oral Tablet; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: NON-ALCOHOLIC STEATOHEPATITIS
Interventions: DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Coronado, California • Montclair, California • Panorama City, California + 12 more

Search by objective public record fields.

Manipulating the Gut Microbiome Study

Slow Digestible Carbohydrates and Exercise in Adolescents With Type 1 Diabetes

Testing Four Feeding Approaches to Oral Feeding in Preterm Infants

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy

A Digital Health Tool for Insulin Titration (DHIT) Individuals With Type 2 Diabetes: A Prospective Outcomes Study With a Retrospective Control Group

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Engaging Mental Effort: Process- and Person-Based Reward Experiences, Effort Reinforcement Intervention, and Cascading Effects on Challenging Tasks

A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

Go Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS®

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Neural Underpinnings of Turning

To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.

Study in Healthy Adult Female Subjects

Circadian Rhythms in Postmenopausal Women

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH